A trial of alpelisib and fulvestrant for breast cancer that has come back or continued to grow after hormone therapy (SOLAR-1)

This trial compared alpelisib and fulvestrant with fulvestrant alone, for people with breast cancer that had grown into surrounding tissue or had spread. It was for men and for postmenopausal women whose cancer:

• had oestrogen receptors, progesterone receptors, or both

• didn’t have the protein HER2

The trial was open for people to join between 2015 and 2017, and the team first published results in 2019.